WCUI - Wellness Center USA, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0450
0.0000 (0.00%)
At close: 3:40PM EDT
Stock chart is not supported by your current browser
Previous Close0.0450
Open0.0501
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0450 - 0.0501
52 Week Range0.0300 - 0.1800
Volume60,000
Avg. Volume34,546
Market Cap4.212M
Beta (3Y Monthly)2.62
PE Ratio (TTM)N/A
EPS (TTM)-0.0430
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    CORRECTION: Psoria-Shield, Inc. and Neo Phototherapy LLC Developing Next Generation LED Phototherapy Device

    HOFFMAN ESTATES, IL, Nov. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Wellness Center USA, Inc. (OTCQB: WCUI) and Psoria-Shield, Inc. (PSI) today announced the formation of a Joint Venture between Psoria-Shield, Inc  and PSI Gen 2 Funding, Inc. (“GEN2”), to further development of their next generation phototherapy device. The Joint Venture will be conducted through Neo Phototherapy, LLC (“NEO”), a recently formed Illinois limited liability company. The next generation Class II medical device is the result of 24 months of product R&D and market research based on the previous Psoria-Light (“PL 1000”) and will utilize a new custom LED emitter array, operate on a new native software platform, use current SOTA high efficient microprocessor systems, and will be smaller, lighter, quieter, and more efficient than the current PL 1000 device.

  • GlobeNewswire

    Psoria-Shield, Inc. and Neo Phototherapy LLC Developing Next Generation LED Phototherapy Device

    HOFFMAN ESTATES, IL, Nov. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Wellness Center USA, Inc. (OTCQB: WCUI) and Psoria-Shield, Inc. (PSI) today announced the formation of a Joint Venture between Psoria-Shield, Inc  and PSI Gen 2 Funding, Inc. (“GEN2”), to further development of their next generation phototherapy device. The Joint Venture will be conducted through Neo Phototherapy, LLC (“NEO”), a recently formed Illinois limited liability company. The next generation Class II medical device is the result of 24 months of product R&D and market research based on the previous Psoria-Light (“PL 1000”) and will utilize a new custom LED emitter array, operate on a new native software platform, use current SOTA high efficient microprocessor systems, and will be smaller, lighter, quieter, and more efficient than the current PL 1000 device.

  • We're sorry this is all we were able to find about this topic.